ReviewSeminars in cell & developmental biology2019
CRISPR-Cas based targeting of host and viral genes as an antiviral strategy.
Review in Seminars in cell & developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Intranasal drop of multiplex RNA therapy for SARS-CoV-2 infections: baicalein-enhanced FEN1 nuclease cleaving as a virus buster.Emerging microbes & infections · 2026Article
- Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure.Microbiology spectrum · 2025Article
- CRISPR/Cas9 Landscape: Current State and Future Perspectives.International journal of molecular sciences · 2023Review
- The Interplay of Genital Herpes with Cellular Processes: A Pathogenesis and Therapeutic Perspective.Viruses · 2023Review
- AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice.EBioMedicine · 2023Article
- CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.Journal of nanobiotechnology · 2022Article
- Association of CRISPR-Cas System with the Antibiotic Resistance and Virulence Genes in Nosocomial Isolates ofInfection and drug resistance · 2022Article
- Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics.Life (Basel, Switzerland) · 2021Review
- Nucleic Acid-Based Technologies Targeting Coronaviruses.Trends in biochemical sciences · 2021Review
- Pathobiology and treatment of viral keratitis.Experimental eye research · 2021Review
- Antiviral therapies: advances and perspectives.Fundamental & clinical pharmacology · 2021Review
- Targeting the Kaposi's sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells.Virology journal · 2021Article
- Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1.Viruses · 2020Article
- A theranostic approach based on radiolabeled antiviral drugs, antibodies and CRISPR-associated proteins for early detection and treatment of SARS-CoV-2 disease.Nuclear medicine communications · 2020Article
- Immunomodulatory roles of human herpesvirus-encoded microRNA in host-virus interaction.Reviews in medical virology · 2020Review
- Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G.Molecular therapy. Nucleic acids · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Viral infections in human are leading cause of mortality and morbidity across the globe. Several viruses (including HIV and Herpesvirus), have evolved ingenious strategies to evade host-immune system and persist life-long. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) is an ancient antiviral system recently discovered in bacteria that has shown tremendous potential as a precise, invariant genome editing tool. Using CRISPR-Cas based system to activate host defenses or genetic modification of viral genome can provide novel, exciting and successful antiviral mechanisms and treatment modalities. In this review, we will provide progress on the CRISPR-Cas based antiviral approaches that facilitate clearance of virus-infected cells and/or prohibit virus infection or replication. We will discuss on the possibilities of CRIPSR-Cas as prophylaxis and therapy in viral infections and review the challenges of this potent gene editing technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.